Search company, investor...
GNS Healthcare company logo

GNS Healthcare

gnshealthcare.com

Founded Year

2000

Stage

Loan | Alive

Total Raised

$65.25M

Last Raised

$1.5M | 3 yrs ago

About GNS Healthcare

GNS Healthcare applies artificial intelligence (AI) platform to unravel the complexity of human disease in order to match the right treatment to the right patient at the right time.

Headquarters Location

196 Broadway

Cambridge, Massachusetts, 02139,

United States

617-374-2300

ESPs containing GNS Healthcare

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Healthcare Providers Tech

Companies in this market reduce the cost of clinical trials by simulating patient cohorts and testing drugs on simulated versions of living entities. Synthetic data vendors use real patient records to create “fake” data that is non-identifiable but still holds predictive power that is useful for drug discovery, clinical trials, and treatment decisions.

GNS Healthcare named as Leader among 8 other companies, including Twin Health, Q Bio, and Syntegra.

Compete with GNS Healthcare?

Ensure that your company and products are accurately represented on our platform.

GNS Healthcare's Products & Differentiators

    Gemini Digital Twin

    Gemini Digital Twins enable the accurate simulation of gene and protein knockdowns at the individual patient level across “digital twins cohorts” to discover and validate novel drug targets. Gemini Digital Twins also enable the simulation of disease progression and drug response at the individual patient level across “digital twins cohorts” to simulate clinical trials to better select patients, and rapidly generate comparative effectiveness evidence.

Research containing GNS Healthcare

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned GNS Healthcare in 2 CB Insights research briefs, most recently on Dec 21, 2020.

Expert Collections containing GNS Healthcare

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GNS Healthcare is included in 8 Expert Collections, including Digital Health.

D

Digital Health

21,956 items

Startups recreating how healthcare is delivered

C

Clinical Trials Tech

364 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.

A

Artificial Intelligence

9,442 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

D

Digital Health 150

150 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

C

Clinical Trials Tech Market Map

108 items

This CB Insights Tech Market Map highlights 100+ clinical trials tech companies that are addressing 8 distinct technology priorities that pharmaceutical companies and CROs face.

B

Biopharma Tech

326 items

Latest GNS Healthcare News

Artificial Intelligence (AI) in Clinical Trials Market is Projected to Reach $4.8 billion by 2027- Exclusive Report by MarketsandMarkets™

Oct 18, 2022

Key Companies Profiled/Vendors IBM corporation | Exscientia | Saama Technologies | Unlearn.AI | Inc. | BioSymetrics | Euretos | Trials.Ai | Insilico Medicine | Ardigen | Pharmaseal | Koninklijke Philips N.V. | Intel | Numerate | AiCure | LLC. | Envisagenics | NURITAs | BioAge Labs | Inc. | Symphony AI. | Median Technologies | Innoplexus | Antidote Technologies | Inc. | GNS Healthcare | Koneksa Health | Halo Health Systems | and DEEP LENS AI The growth of this market is driven by the growing need to control development costs & reduce time involved in drug development, and Increasing adoption of AI based platform to improve productivity and efficiency of clinical trials, On the other hand, a lack of data sets in the field of clinical trials and the inadequate availability of skilled labor are some of the factors challenging the growth of the market “Services segment is expected to grow at the highest rate during the forecast period” Based on offering, the AI in clinical trials market is segmented into software and services. In 2021, the services segment accounted for the largest market share of the global AI in clinical trials services market and also expected to grow at the highest CAGR during the forecast period. The benefits associated with AI services and the strong demand for AI services among end users are the key factors driving the growth of this market segment. “Machine learning technology segment accounted for the largest share of the global AI in clinical trials market” Based on technology, the Artificial Intelligence (AI) in Clinical Trials Market is segmented into machine learning and other technologies. The machine learning segment accounted for the largest share of the global market in 2021 and expected to grow at the highest CAGR during the forecast period. The machine learning technology segment further segmented into deep learning, supervised learning, and other machine learning technologies. Deep learning segment accounted for the largest share of the market in 2021, and this segment also expected to grow at the highest CAGR during the forecast period. “The oncology application segment accounted for the largest share of the AI in clinical trials market in 2021” On the basis of application, the Artificial Intelligence (AI) in Clinical Trials Market is segmented into neurological diseases and condition, cardiovascular diseases, metabolic diseases, infectious disease, immunology diseases, and other applications. The oncology segment accounted for the largest share of the market in 2021, owing to the increasing demand for effective cancer drugs and a large number of drug trials in the field of oncology is contributing to the adoption of AI-enabled technologies in this application area. Also, many players are developing and adopting oncology-based AI tools for clinical trials, thus impelling the segment growth. The infectious diseases segment is estimated to register the highest CAGR during the forecast period, owing to the increasing number of clinical trials for vaccine and drugs for covid-19 and other infectious disease and rising investment in R&D for infectious diseases. “Pharmaceutical & biotechnology companies segment accounted for the largest share of the global AI in clinical trials market” On the basis of end user, the Artificial Intelligence (AI) in Clinical Trials Market is segmented into pharmaceutical & biotechnology companies, CROs, and other end users. The pharmaceutical & biotechnology companies segment accounted for the largest market share of Artificial Intelligence in Clinical Trials Market, in 2021. Factors such as increasing adoption of AI enabled technologies to improve productivity and efficiency of clinical trials. Furthermore, growing cross industry collaborations and partnership for leverging the AI solution for R&D and the overall development process. Hence driving the growth among this end user segment. Geographical Growth Scenario: North America accounted for the largest share of the global AI in clinical trials market in 2021 and also expected to grow at the highest CAGR during the forecast period. North America, which comprises the US, and Canada forms the largest market for AI in clinical trials. These countries have been early adopters of AI technology in clinical trials and development. Presence of key established players, well-established pharmaceutical and biotechnology industry, and high focus on R&D & substantial investment are some of the key factors responsible for the large share and high growth rate of this market Key Players: Prominent players in this Artificial Intelligence in Clinical Trials Market are IBM corporation, Exscientia, Saama Technologies, Unlearn.AI, Inc., BioSymetrics, Euretos, Trials.Ai, Insilico Medicine, Ardigen, Pharmaseal, Koninklijke Philips N.V., Intel, Numerate, AiCure, LLC., Envisagenics, NURITAs, BioAge Labs, Inc., Symphony AI., Median Technologies, Innoplexus, Antidote Technologies, Inc., GNS Healthcare, Koneksa Health, Halo Health Systems, and DEEP LENS AI. Players adopted organic as well as inorganic growth strategies such as product upgrades, collaborations, agreements, partnerships, and acquisitions to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market. Contact Data About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.Contact:Mr. Aashish MehraMarketsandMarkets™ INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: sales@marketsandmarkets.com

GNS Healthcare Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

GNS Healthcare Rank

GNS Healthcare Frequently Asked Questions (FAQ)

  • When was GNS Healthcare founded?

    GNS Healthcare was founded in 2000.

  • Where is GNS Healthcare's headquarters?

    GNS Healthcare's headquarters is located at 196 Broadway, Cambridge.

  • What is GNS Healthcare's latest funding round?

    GNS Healthcare's latest funding round is Loan.

  • How much did GNS Healthcare raise?

    GNS Healthcare raised a total of $65.25M.

  • Who are the investors of GNS Healthcare?

    Investors of GNS Healthcare include Paycheck Protection Program, Merck Global Health Innovation Fund, Alexandria Venture Investments, Celgene, Amgen Ventures and 11 more.

  • Who are GNS Healthcare's competitors?

    Competitors of GNS Healthcare include Insilico Medicine, Cyclica, Recursion, Owkin, AnaBios, BenevolentAI, Unlearn, Exscientia, Standigm, Virtonomy and 13 more.

  • What products does GNS Healthcare offer?

    GNS Healthcare's products include Gemini Digital Twin and 1 more.

  • Who are GNS Healthcare's customers?

    Customers of GNS Healthcare include Pfizer, Mercks, AbbVie, Sanofi and Servier.

Compare GNS Healthcare to Competitors

Standigm Logo
Standigm

Standigm is an AI and systems biology-based startup that aims to expedite the drug discovery process. Standigm develops a computer modeling technology that learns medical and biological information and predicts the action mechanism of pharmaceutics in advance. This technology can improve the pharmaceutical development process by tailoring the application of previous know-hows, come up with possible combinations of pharmaceuticals, and optimize the selection of candidates and participants for clinical trials.

My Intelligent Machines Logo
My Intelligent Machines

My Intelligent Machines is a platform as a service helping biologists analyze genomic data using AI. The platform finds the appropriate algorithms to analyze the user's data and generates text on its methods of analysis.

Insilico Medicine Logo
Insilico Medicine

Insilico Medicine develops a range of Generative Adversarial Networks (GANs) and reinforcement learning approaches to identify protein targets, generate molecular structures with specified properties, and generate synthetic data. The company provides pharmaceutical and biotechnology companies with artificial intelligence solutions for research and development. It was founded in 2014 and is based in Hong Kong.

Healx Logo
Healx

Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Its AI drug discovery platform leverages public and proprietary biomedical data and features a knowledge graph for rare diseases.

B
BERG

BERG is a Boston-based biopharma company focused on taking a bold "back to biology" approach to therapeutic discovery using its unique AI-based Interrogative Biology platform. This platform combines patient biology and artificial intelligence-based analytics to engage the differences between healthy and disease environments. The patient's own biology drives the platform's results and guides the company in the discovery and development of drugs, diagnostics and healthcare applications. Its platform utilizes patient population health data to bring actionable Patient Intelligence to precision medicine applications. This means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems.

Atomwise Logo
Atomwise

Atomwise uses deep learning neural networks to help discover new medicines. Atomwise achieves results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, start-ups, and research institutions. It is currently using computational drug design to design drugs against COVID.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.